Marcella Martignoni

2.5k total citations · 1 hit paper
22 papers, 1.8k citations indexed

About

Marcella Martignoni is a scholar working on Oncology, Molecular Biology and Pharmacology. According to data from OpenAlex, Marcella Martignoni has authored 22 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 7 papers in Molecular Biology and 7 papers in Pharmacology. Recurrent topics in Marcella Martignoni's work include Drug Transport and Resistance Mechanisms (8 papers), Pharmacogenetics and Drug Metabolism (7 papers) and Cancer Treatment and Pharmacology (5 papers). Marcella Martignoni is often cited by papers focused on Drug Transport and Resistance Mechanisms (8 papers), Pharmacogenetics and Drug Metabolism (7 papers) and Cancer Treatment and Pharmacology (5 papers). Marcella Martignoni collaborates with scholars based in Italy, United Kingdom and United States. Marcella Martignoni's co-authors include Ruben de Kanter, Geny M. M. Groothuis, Mario Monshouwer, Fiona Thistlethwaite, Alessandra di Pietro, Toni K. Choueiri, James Larkin, Paul Nathan, Michael S. Gordon and Hirotsugu Uemura and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Annals of Oncology.

In The Last Decade

Marcella Martignoni

22 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction

2006 1.1k citations Marcella Martignoni, Geny M. M. Groothuis et al. Expert Opinion on Drug Metabolism & Toxicology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marcella Martignoni Italy	12	684	646	546	249	146	22	1.8k
Jinping Gan United States	22	436 0.6×	466 0.7×	569 1.0×	123 0.5×	100 0.7×	61	1.7k
Tomomi Furihata Japan	28	270 0.4×	485 0.8×	748 1.4×	98 0.4×	124 0.8×	98	1.9k
Lena Gustavsson Sweden	24	350 0.5×	453 0.7×	1.0k 1.9×	141 0.6×	63 0.4×	58	2.5k
Theresia Thalhammer Austria	29	204 0.3×	662 1.0×	837 1.5×	116 0.5×	203 1.4×	79	2.4k
Christoph Köhle Germany	25	411 0.6×	343 0.5×	1.1k 2.0×	75 0.3×	395 2.7×	38	2.3k
József Mandl Hungary	33	335 0.5×	183 0.3×	1.3k 2.5×	202 0.8×	183 1.3×	108	3.0k
Colin Brown United Kingdom	26	220 0.3×	803 1.2×	1.0k 1.9×	121 0.5×	57 0.4×	58	2.1k
Evita van de Steeg Netherlands	29	469 0.7×	1.2k 1.8×	619 1.1×	85 0.3×	54 0.4×	59	2.5k
Ryan W. Dellinger United States	24	384 0.6×	592 0.9×	1.0k 1.9×	64 0.3×	157 1.1×	39	2.3k
Yan Weng China	29	471 0.7×	336 0.5×	1.4k 2.6×	68 0.3×	175 1.2×	86	2.7k

Countries citing papers authored by Marcella Martignoni

Since Specialization

Citations

This map shows the geographic impact of Marcella Martignoni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marcella Martignoni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marcella Martignoni more than expected).

Fields of papers citing papers by Marcella Martignoni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marcella Martignoni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marcella Martignoni. The network helps show where Marcella Martignoni may publish in the future.

Co-authorship network of co-authors of Marcella Martignoni

This figure shows the co-authorship network connecting the top 25 collaborators of Marcella Martignoni. A scholar is included among the top collaborators of Marcella Martignoni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marcella Martignoni. Marcella Martignoni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hamilton, Erika, Michelino De Laurentiis, Komal Jhaveri, et al.. (2025). Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study.. Journal of Clinical Oncology. 43(17_suppl). 1 indexed citations

Larkin, James, Mototsugu Oya, Marcella Martignoni, et al.. (2022). Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial. The Oncologist. 28(4). 333–340. 10 indexed citations

Martignoni, Marcella, M. Strolin Benedetti, Gavin P. Davey, Keith F. Tipton, & Andrew G. McDonald. (2020). Degradation of thymic humoral factor γ2 in human, rat and mouse blood: An experimental and theoretical study. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics. 1868(9). 140467–140467. 1 indexed citations

Choueiri, Toni K., James Larkin, Mototsugu Oya, et al.. (2018). Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. The Lancet Oncology. 19(4). 451–460. 207 indexed citations

Larkin, James, Michael S. Gordon, Fiona Thistlethwaite, et al.. (2016). Avelumab (MSB0010718C; anti-PD-L1) in combination with axitinib as first-line treatment for patients with advanced renal cell carcinoma.. Journal of Clinical Oncology. 34(15_suppl). TPS4580–TPS4580. 11 indexed citations

Braud, Filippo de, Monica Niger, Silvia Damian, et al.. (2015). Alka-372-001: First-in-human, phase I study of entrectinib – an oral pan-trk, ROS1, and ALK inhibitor – in patients with advanced solid tumors with relevant molecular alterations.. Journal of Clinical Oncology. 33(15_suppl). 2517–2517. 41 indexed citations

Braud, Filippo de, Lorenzo Pilla, Monica Niger, et al.. (2014). Rxdx-101, an Oral Pan-Trk, Ros1, and Alk Inhibitor, in Patients with Advanced Solid Tumors with Relevant Molecular Alterations. Annals of Oncology. 25. iv148–iv148. 7 indexed citations

Braud, Filippo de, Lorenzo Pilla, Monica Niger, et al.. (2014). Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations.. Journal of Clinical Oncology. 32(15_suppl). 2502–2502. 27 indexed citations

Vogl, Thomas J., Gennaro Gadaleta‐Caldarola, Mark R. Middleton, et al.. (2013). Phase II trial of nemorubicin hydrochloride (N) in combination with cisplatin (cDDP) administered by intra-hepatic artery (IHA) in patients (pts) with hepatocellular carcinoma (HCC): Final results.. Journal of Clinical Oncology. 31(15_suppl). e15061–e15061. 1 indexed citations

10.

Izzo, Francesco, Annamaria Catino, Thomas J. Vogl, et al.. (2009). Phase II trial of nemorubicin hydrocloride (nemorubicin) in combination with cisplatin (cDDP) in patients (pts) with hepatocellular carcinoma (HCC): First step results. Journal of Clinical Oncology. 27(15_suppl). 4593–4593. 1 indexed citations

11.

Martignoni, Marcella. (2006). Species and strain differences in drug metabolism in liver and intestine. Data Archiving and Networked Services (DANS). 6 indexed citations

12.

Martignoni, Marcella, Geny M. M. Groothuis, & Ruben de Kanter. (2006). Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opinion on Drug Metabolism & Toxicology. 2(6). 875–894. 1124 indexed citations breakdown →

13.

Martignoni, Marcella, Geny M. M. Groothuis, & Ruben de Kanter. (2006). COMPARISON OF MOUSE AND RAT CYTOCHROME P450-MEDIATED METABOLISM IN LIVER AND INTESTINE. Drug Metabolism and Disposition. 34(6). 1047–1054. 89 indexed citations

14.

Martignoni, Marcella, et al.. (2005). An in vivo and in vitro comparison of CYP gene induction in mice using liver slices and quantitative RT-PCR. Toxicology in Vitro. 20(1). 125–131. 21 indexed citations

15.

Kanter, Ruben de, Esther van de Kerkhof, Marcella Martignoni, et al.. (2004). A new technique for preparing precision-cut slices from small intestine and colon for drug biotransformation studies. Journal of Pharmacological and Toxicological Methods. 51(1). 65–72. 48 indexed citations

16.

Martignoni, Marcella, et al.. (2004). An in vivo and in vitro comparison of CYP induction in rat liver and intestine using slices and quantitative RT-PCR. Chemico-Biological Interactions. 151(1). 1–11. 52 indexed citations

17.

Martignoni, Marcella, et al.. (2004). Lack of strain-related differences in drug metabolism and efflux transporter characteristics between CD-1 and athymic nude mice. Cancer Chemotherapy and Pharmacology. 55(2). 129–135. 11 indexed citations

18.

Martignoni, Marcella, et al.. (2003). Phase I and phase II metabolic activities are retained in liver slices from mouse, rat, dog, monkey and human after cryopreservation. Toxicology in Vitro. 18(1). 121–128. 28 indexed citations

19.

Benedetti, M. Strolin, et al.. (1995). Chapter 13 Enantioselective recognition of two anticonvulsants, FCE 26743 and FCE 28073, by MAO, and relationship between MAO-B inhibition and FCE 26743 concentrations in rat brain. Progress in brain research. 106. 123–134. 57 indexed citations

20.

Battaglia, R., et al.. (1995). In vitro metabolism of THF-γ2 in human, Rat and mouse blood. Pharmacological Research. 31. 46–46. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact